ABBISKO-B(02256): Hoya Pharmaceuticals announced that the new oral small molecule pan-KRAS inhibitor ABSK211 has received FDA approval for clinical trial application.
Hoyu-B (02256) announced that its subsidiary Shanghai Hoyu Biopharmaceutical Technology Co., Ltd. (Hoyu Medicine) has obtained approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for ABSK211, an oral, highly potent, and highly selective small molecule pan-KRAS inhibitor for the treatment of advanced solid tumor patients with KRAS gene mutations that the company is currently researching. This is a voluntary announcement issued by the company. The group cannot guarantee that ABSK211 will ultimately be successful in obtaining market approval.
Announcement: ABBISKO-B (02256) announces that its subsidiary company, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Medicine), has received approval from the U.S. Food and Drug Administration (FDA) for the new drug clinical trial application (IND) of ABSK211, an oral, highly potent, and highly selective small molecule pan-KRAS inhibitor for the treatment of late-stage solid tumor patients with KRAS gene mutations. This announcement is made voluntarily by the company. The group cannot guarantee that ABSK211 will ultimately be approved for market.
Related Articles
New Stock Outlook | Can Xintianxia Benefit from the Upturn in the Flash Memory Industry and Achieve Performance Reversal, Seize the Opportunity to Lay Out "AI+" to Break Free from Cyclical Constraints?
Preview of Citibank Q2 software industry financial report: AI budget will concentrate on "data infrastructure leaders", these US stocks will emerge as winners.
Bounce back from the bottom! XUNCE (03317) TokenOS lands in Europe, and order-driven ARR grows strongly.
New Stock Outlook | Can Xintianxia Benefit from the Upturn in the Flash Memory Industry and Achieve Performance Reversal, Seize the Opportunity to Lay Out "AI+" to Break Free from Cyclical Constraints?
Preview of Citibank Q2 software industry financial report: AI budget will concentrate on "data infrastructure leaders", these US stocks will emerge as winners.
Bounce back from the bottom! XUNCE (03317) TokenOS lands in Europe, and order-driven ARR grows strongly.
RECOMMEND
